Dow Jones
38.225,66 +322,37 (+0,85%) Nasdaq
15.840,96 +235,48 (+1,51%) Nikkei 225
38.236,07 -37,98 (-0,10%) EUR/USD
1,0731 +0,0013 (+0,12%) Bitcoin EUR
55.270,67 +1.960,56 (+3,68%) CMC Crypto 200
1.277,94 +7,19 (+0,57%)
GILD Jan 2026 72.500 put
| Chiusura precedente | 12,10 |
| Aperto | 12,10 |
| Denaro | 11,65 |
| Lettera | 12,25 |
| Prezzo d'esercizio | 72,50 |
| Scadenza | 2026-01-16 |
| Min-Max giorno | 12,10 - 12,10 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 114 |
GlobeNewswireGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswireCenter for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care. Despite the availability of existing tr
